Abirium Abiraterone Acetate Tablets 250 mg is a prescription oral oncology medicine identified as containing Abiraterone Acetate 250 mg per tablet.

Abiraterone acetate is a prodrug converted to abiraterone, a CYP17A1 inhibitor.

CYP17A1 is an enzyme involved in androgen biosynthesis.

By inhibiting CYP17A1, abiraterone reduces androgen production in the testes, adrenal glands and prostate tumor tissue.

Abiraterone acetate is used in selected advanced prostate cancer treatment settings, including metastatic castration-resistant prostate cancer and metastatic high-risk castration-sensitive prostate cancer, depending on applicable approvals.

It is generally administered with a corticosteroid such as prednisone or prednisolone, alongside appropriate androgen deprivation therapy unless the patient has undergone bilateral orchiectomy.

The stated 250 mg tablet strength does not establish the prescribed daily dose. The treating oncologist determines the appropriate regimen and any necessary dose adjustments.

The exact manufacturer, pack size, tablet composition, storage conditions and approved indications of Abirium must be verified from its approved Indian product documentation.

Marketed by Essentials Emporium Enterprises, Abirium is listed within the oncology pharmaceutical category for hospitals, cancer treatment centres and authorized pharmaceutical buyers.

Key Product Features